JAGX

Jaguar Animal Health Inc

JAGX, USA

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

https://jaguar.health

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
JAGX
stock
JAGX

Jaguar trial cuts children’s IV support needs by up to 37% Stock Titan

Read more →
JAGX
stock
JAGX

Wall Street Recap: Can Centurion Acquisition Corp Equity Warrant scale operations efficiently - July 2025 Setups & Verified Entry Point Detection baoquankhu1.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$25.5

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.29

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-168.86 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-19.21 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-153.84 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

8.02

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.93% of the total shares of Jaguar Animal Health Inc

1.

UBS Group AG

(0.5137%)

since

2025/06/30

2.

Fidelity Extended Market Index

(0.1339%)

since

2025/07/31

3.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0752%)

since

2025/07/31

4.

Tower Research Capital LLC

(0.0732%)

since

2025/06/30

5.

Royal Bank of Canada

(0.0323%)

since

2025/06/30

6.

Fidelity Total Market Index

(0.0318%)

since

2025/07/31

7.

Fidelity Series Total Market Index

(0.0292%)

since

2025/07/31

8.

NT Ext Equity Mkt Idx Fd - L

(0.0095%)

since

2025/06/30

9.

Northern Trust Extended Eq Market Idx

(0.0095%)

since

2025/06/30

10.

SBI Securities Co Ltd

(0.0092%)

since

2025/06/30

11.

Spartan Total Market Index Pool G

(0.0071%)

since

2025/07/31

12.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0027%)

since

2025/06/30

13.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0023%)

since

2024/12/31

14.

Northern Trust Wilshire 5000

(0.0006%)

since

2025/06/30

15.

Morgan Stanley - Brokerage Accounts

(0.0005%)

since

2025/06/30

16.

BlackRock Inc

(0.0002%)

since

2025/06/30

17.

Bank of America Corp

(0.0002%)

since

2025/06/30

18.

State Street Corp

(0%)

since

2025/03/31

20.

Vanguard Group Inc

(0%)

since

2025/03/31

21.

Geode Capital Management, LLC

(0%)

since

2025/03/31

22.

Virtu Financial LLC

(0%)

since

2025/03/31

23.

HRT FINANCIAL LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-6.28

EPS Estimate

-0.22

EPS Difference

-6.06

Surprise Percent

-2754.5455%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(1)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.